会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • LENTICULES FOR INTRASTROMAL CORNEAL IMPLANTATION
    • 隐形眼角膜植入术
    • WO2018047151A1
    • 2018-03-15
    • PCT/IB2017/055505
    • 2017-09-12
    • GEBAUER-KLOPOTEK PATENT VERWALTUNGS-UG
    • KLOPOTEK, Peter J.
    • A61F2/14A61F9/007A61K35/12
    • A61F2/142A61F9/007A61K35/12A61K35/30A61L27/3633A61L27/3641A61L27/3687A61L2430/16
    • Decellularized and shaped corneal tissue lenticules from allograft and/or xenograft sources and methods of obtaining such lenticules are disclosed. The lenticules are particularly useful as intrastromal lenticular implants in keratoplasty procedures, in which a hinged flap is formed in a patient's cornea and folded back along its hinge to expose the stromal bed of the cornea. The shaped lenticule is then applied to the stromal bed and the flap returned to its original position yielding a new curvature for the cornea and resulting in a desired refractive correction. Fine-tuning of the new refractive power can be achieved by laser ablation either at the same time as implantation or at later time in the event of regression or tonus changes. Methods of decellularizing cornea tissue are disclosed to reduce potential immunogenic reactions on the part of the patient to the implanted lenticule. The lenticules can be further treated to remove immunogenic epitopes. In addition, the posterior and/or anterior surfaces of the lenticule can be treated to assist in intrastromal seating of the lenticule and/or to reduce the likelihood of dislodgement. The methods of forming lenticules can further include preserving at least a portion of the Bowman's membrane. The smoothness of the Bowman's membrane surface also makes it less likely that reopening the flap will dislodge the lenticule.
    • 公开了来自同种异体移植物和/或异种移植物源的脱细胞形状的角膜组织微透镜和获得这种微透镜的方法。 微透镜特别适用于角膜移植手术中的基质内透镜植入物,其中在患者的角膜中形成铰接瓣并沿其铰链折回以暴露角膜的基质床。 然后将成形的微透镜施加到基质床并且瓣返回到其初始位置,产生角膜的新曲率并且导致期望的屈光矫正。 新的屈光力的微调可以通过激光烧蚀来实现,或者在植入的同时进行,或者在晚些时候进行回归或张力改变。 公开了使角膜组织脱细胞的方法,以减少患者部分对植入的微透镜的潜在的免疫原性反应。 微透镜可以进一步处理以去除免疫原性表位。 此外,微透镜的后表面和/或前表面可以被处理以帮助微透镜的基质内定位和/或降低移位的可能性。 形成微透镜的方法可以进一步包括保存至少一部分鲍曼膜。 鲍曼膜表面的光滑度也使得重新打开翻盖不太可能移出微透镜。
    • 8. 发明申请
    • INJECTABLE AMNIOTIC MEMBRANE TISSUE GRAFT
    • 可注射的生物膜组织切片
    • WO2016109828A1
    • 2016-07-07
    • PCT/US2015/068334
    • 2015-12-31
    • APPLIED BIOLOGICS, LLC
    • BRITT, Edward
    • A61L27/36
    • A61L27/3633A61K35/50A61L27/3604A61L27/3645A61L2400/06A61L2430/34
    • The invention relates to an injectable amniotic membrane tissue graft product for percutaneous, minimally invasive, surgical, and topical therapy of injury and disease and methods of applying such tissue grafts to a subject at a particular location. The injectable preparations maximize and standardize available quantities of non-cellular biological compounds to enhance therapeutic efficacy. The tissue graft preparations are semi-viscous fluids with standardized properties which may be intraoperatively transplanted at the recipient site using a needless syringe, by non-operative percutaneous injection through a hypodermic needle, or direct topical application to open cutaneous wounds and external soft tissue defects.
    • 本发明涉及一种用于经皮,微创,手术和局部治疗损伤和疾病的可注射羊膜组织移植产品,以及在特定位置将这种组织移植物施用于受试者的方法。 可注射制剂使可用量的非细胞生物化合物最大化并标准化以增强治疗功效。 组织移植物制剂是具有标准化性质的半粘性流体,其可以使用不需要的注射器在受体部位进行术中移植,通过皮下注射针的非手术经皮注射,或直接局部应用于开放的皮肤伤口和外部软组织缺陷 。